{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:14:30Z","timestamp":1785777270836,"version":"3.56.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10689-020-00189-y","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T02:03:26Z","timestamp":1591581806000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Chemoprevention in familial adenomatous polyposis: past, present and future"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-3889","authenticated-orcid":false,"given":"Phillip M.","family":"Kemp Bohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Mankaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Chick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Cindass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies T.","family":"Hickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Ensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vance","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Travis","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Peoples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"189_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1172-4-22","volume":"4","author":"E Half","year":"2009","unstructured":"Half E, Bercovich D, Rozen P (2009) Familial adenomatous polyposis. Orphanet J Rare Dis 4:22. https:\/\/doi.org\/10.1186\/1750-1172-4-22","journal-title":"Orphanet J Rare Dis"},{"issue":"44","key":"189_CR2","doi-asserted-by":"publisher","first-page":"16620","DOI":"10.3748\/wjg.v20.i44.16620","volume":"20","author":"FG Campos","year":"2014","unstructured":"Campos FG (2014) Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. World J Gastroenterol 20(44):16620\u201316629. https:\/\/doi.org\/10.3748\/wjg.v20.i44.16620","journal-title":"World J Gastroenterol"},{"issue":"1","key":"189_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2017.09.020","volume":"21","author":"S Aguera-Gonzalez","year":"2017","unstructured":"Aguera-Gonzalez S, Burton OT, Vazquez-Chavez E, Cuche C, Herit F, Bouchet J, Lasserre R, Del Rio-Iniguez I, Di Bartolo V, Alcover A (2017) Adenomatous polyposis coli defines Treg differentiation and anti-inflammatory function through microtubule-mediated NFAT localization. Cell Rep 21(1):181\u2013194. https:\/\/doi.org\/10.1016\/j.celrep.2017.09.020","journal-title":"Cell Rep"},{"issue":"13","key":"189_CR4","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1158\/0008-5472.Can-09-0304","volume":"69","author":"E Gounaris","year":"2009","unstructured":"Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F, Khazaie K (2009) T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69(13):5490\u20135497. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-0304","journal-title":"Cancer Res"},{"issue":"2","key":"189_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/humu.1380030206","volume":"3","author":"ML Bisgaard","year":"1994","unstructured":"Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121\u2013125. https:\/\/doi.org\/10.1002\/humu.1380030206","journal-title":"Hum Mutat"},{"issue":"3","key":"189_CR6","first-page":"201","volume":"25","author":"VN Tudyka","year":"2012","unstructured":"Tudyka VN, Clark SK (2012) Surgical treatment in familial adenomatous polyposis. Ann Gastroenterol 25(3):201\u2013206","journal-title":"Ann Gastroenterol"},{"issue":"9","key":"189_CR7","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1200\/jco.2003.09.118","volume":"21","author":"L Bertario","year":"2003","unstructured":"Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P (2003) Multiple approach to the exploration of genotype\u2013phenotype correlations in familial adenomatous polyposis. J Clin Oncol 21(9):1698\u20131707. https:\/\/doi.org\/10.1200\/jco.2003.09.118","journal-title":"J Clin Oncol"},{"issue":"13","key":"189_CR8","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1158\/1078-0432.Ccr-17-0790","volume":"23","author":"MI Achatz","year":"2017","unstructured":"Achatz MI, Porter CC, Brugieres L, Druker H, Frebourg T, Foulkes WD, Kratz CP, Kuiper RP, Hansford JR, Hernandez HS, Nathanson KL, Kohlmann WK, Doros L, Onel K, Schneider KW, Scollon SR, Tabori U, Tomlinson GE, Evans DGR, Plon SE (2017) Cancer screening recommendations and clinical management of inherited gastrointestinal cancer syndromes in childhood. Clin Cancer Res 23(13):e107\u2013e114. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0790","journal-title":"Clin Cancer Res"},{"issue":"2","key":"189_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","volume":"110","author":"S Syngal","year":"2015","unstructured":"Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223\u2013262","journal-title":"Am J Gastroenterol"},{"key":"189_CR10","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Colorectal (2019) National Comprehensvie Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf. Accessed 2 Jan 2020"},{"issue":"1","key":"189_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10689-018-0097-z","volume":"18","author":"M Monachese","year":"2019","unstructured":"Monachese M, Mankaney G, Lopez R, O'Malley M, Laguardia L, Kalady MF, Church J, Shin J, Burke CA (2019) Outcome of thyroid ultrasound screening in FAP patients with a normal baseline exam. Fam Cancer 18(1):75\u201382. https:\/\/doi.org\/10.1007\/s10689-018-0097-z","journal-title":"Fam Cancer"},{"issue":"3","key":"189_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/thy.2014.0107","volume":"25","author":"X Feng","year":"2015","unstructured":"Feng X, Milas M, O'Malley M, LaGuardia L, Berber E, Jin J, Metzger R, Mitchell J, Shin J, Burke CA, Kalady M, Church J, Siperstein A (2015) Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid 25(3):325\u2013332. https:\/\/doi.org\/10.1089\/thy.2014.0107","journal-title":"Thyroid"},{"issue":"4\u20135","key":"189_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpg.2011.08.002","volume":"25","author":"B Kim","year":"2011","unstructured":"Kim B, Giardiello FM (2011) Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol 25(4\u20135):607\u2013622. https:\/\/doi.org\/10.1016\/j.bpg.2011.08.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"7","key":"189_CR14","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1365-2559.2008.03038.x","volume":"52","author":"MH McLean","year":"2008","unstructured":"McLean MH, Murray GI, Fyfe N, Hold GL, Mowat NA, El-Omar EM (2008) COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology 52(7):806\u2013815. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03038.x","journal-title":"Histopathology"},{"issue":"19","key":"189_CR15","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.Ccr-10-0356","volume":"16","author":"L Gattinoni","year":"2010","unstructured":"Gattinoni L, Ji Y, Restifo NP (2010) Wnt\/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res 16(19):4695\u20134701. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-0356","journal-title":"Clin Cancer Res"},{"issue":"4","key":"189_CR16","doi-asserted-by":"publisher","first-page":"e18562","DOI":"10.1371\/journal.pone.0018562","volume":"6","author":"F Nunez","year":"2011","unstructured":"Nunez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV (2011) Wnt\/beta-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. PLoS ONE 6(4):e18562. https:\/\/doi.org\/10.1371\/journal.pone.0018562","journal-title":"PLoS ONE"},{"issue":"29","key":"189_CR17","doi-asserted-by":"publisher","first-page":"20474","DOI":"10.1074\/jbc.M602859200","volume":"281","author":"AL Eisinger","year":"2006","unstructured":"Eisinger AL, Nadauld LD, Shelton DN, Peterson PW, Phelps RA, Chidester S, Stafforini DM, Prescott SM, Jones DA (2006) The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem 281(29):20474\u201320482. https:\/\/doi.org\/10.1074\/jbc.M602859200","journal-title":"J Biol Chem"},{"issue":"5","key":"189_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803\u2013809. https:\/\/doi.org\/10.1016\/s0092-8674(00)81988-1","journal-title":"Cell"},{"issue":"4","key":"189_CR19","first-page":"1733","volume":"61","author":"M Oshima","year":"2001","unstructured":"Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM, Evans JF (2001) Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61(4):1733\u20131740","journal-title":"Cancer Res"},{"issue":"1","key":"189_CR20","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41598-017-06253-5","volume":"7","author":"MA Hull","year":"2017","unstructured":"Hull MA, Cuthbert RJ, Ko CWS, Scott DJ, Cartwright EJ, Hawcroft G, Perry SL, Ingram N, Carr IM, Markham AF, Bonifer C, Coletta PL (2017) Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min\/+) mouse model of intestinal tumorigenesis. Sci Rep 7(1):6074. https:\/\/doi.org\/10.1038\/s41598-017-06253-5","journal-title":"Sci Rep"},{"issue":"26","key":"189_CR21","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/nejm200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946\u20131952. https:\/\/doi.org\/10.1056\/nejm200006293422603","journal-title":"N Engl J Med"},{"issue":"6","key":"189_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/gut.50.6.857","volume":"50","author":"RK Phillips","year":"2002","unstructured":"Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857\u2013860. https:\/\/doi.org\/10.1136\/gut.50.6.857","journal-title":"Gut"},{"key":"189_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/ceg.S121841","volume":"10","author":"CA Burke","year":"2017","unstructured":"Burke CA, Phillips R, Berger MF, Li C, Essex MN, Iorga D, Lynch PM (2017) Children's International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 10:177\u2013185. https:\/\/doi.org\/10.2147\/ceg.S121841","journal-title":"Clin Exp Gastroenterol"},{"issue":"11","key":"189_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092\u20131102. https:\/\/doi.org\/10.1056\/NEJMoa050493","journal-title":"N Engl J Med"},{"issue":"11","key":"189_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071\u20131080. https:\/\/doi.org\/10.1056\/NEJMoa050405","journal-title":"N Engl J Med"},{"issue":"18","key":"189_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/nejm199305063281805","volume":"328","author":"FM Giardiello","year":"1993","unstructured":"Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328(18):1313\u20131316. https:\/\/doi.org\/10.1056\/nejm199305063281805","journal-title":"N Engl J Med"},{"issue":"14","key":"189_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMoa012015","volume":"346","author":"FM Giardiello","year":"2002","unstructured":"Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346(14):1054\u20131059. https:\/\/doi.org\/10.1056\/NEJMoa012015","journal-title":"N Engl J Med"},{"issue":"5","key":"189_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1940-6207.Capr-11-0106","volume":"4","author":"J Burn","year":"2011","unstructured":"Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, Maher ER, Moslein G, Vasen HF, Coaker J, Phillips RK, Bulow S, Mathers JC (2011) A randomized placebo-controlled prevention trial of aspirin and\/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4(5):655\u2013665. https:\/\/doi.org\/10.1158\/1940-6207.Capr-11-0106","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"189_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/cam4.46","volume":"2","author":"H Ishikawa","year":"2013","unstructured":"Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T (2013) Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med 2(1):50\u201356. https:\/\/doi.org\/10.1002\/cam4.46","journal-title":"Cancer Med"},{"issue":"4","key":"189_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gheart.2014.08.001","volume":"9","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr (2014) World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Glob Heart 9(4):457\u2013467. https:\/\/doi.org\/10.1016\/j.gheart.2014.08.001","journal-title":"Glob Heart"},{"issue":"9809","key":"189_CR31","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/s0140-6736(11)61049-0","volume":"378","author":"J Burn","year":"2011","unstructured":"Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081\u20132087. https:\/\/doi.org\/10.1016\/s0140-6736(11)61049-0","journal-title":"Lancet"},{"issue":"2","key":"189_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","volume":"159","author":"NR Cook","year":"2013","unstructured":"Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159(2):77\u201385. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00002","journal-title":"Ann Intern Med"},{"issue":"2","key":"189_CR33","first-page":"199","volume":"57","author":"FM Giardiello","year":"1997","unstructured":"Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr (1997) Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57(2):199\u2013201","journal-title":"Cancer Res"},{"issue":"10","key":"189_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrc1454","volume":"4","author":"EW Gerner","year":"2004","unstructured":"Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4(10):781\u2013792. https:\/\/doi.org\/10.1038\/nrc1454","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"189_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/01635580802401317","volume":"60","author":"NA Ignatenko","year":"2008","unstructured":"Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW (2008) Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60(Suppl 1):30\u201335. https:\/\/doi.org\/10.1080\/01635580802401317","journal-title":"Nutr Cancer"},{"issue":"1","key":"189_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1940-6207.Capr-08-0042","volume":"1","author":"FL Meyskens Jr","year":"2008","unstructured":"Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1(1):32\u201338. https:\/\/doi.org\/10.1158\/1940-6207.Capr-08-0042","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"189_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/gutjnl-2014-307235","volume":"65","author":"PM Lynch","year":"2016","unstructured":"Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E (2016) An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 65(2):286\u2013295. https:\/\/doi.org\/10.1136\/gutjnl-2014-307235","journal-title":"Gut"},{"issue":"1","key":"189_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12876-016-0494-4","volume":"16","author":"CA Burke","year":"2016","unstructured":"Burke CA, Dekker E, Samadder NJ, Stoffel E, Cohen A (2016) Efficacy and safety of eflornithine (CPP-1X)\/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, phase III trial. BMC Gastroenterol 16(1):87. https:\/\/doi.org\/10.1186\/s12876-016-0494-4","journal-title":"BMC Gastroenterol"},{"key":"189_CR39","doi-asserted-by":"crossref","unstructured":"Burke CA SN, Dekker E, et al (2019) Safety and efficacy of combined CPP-1X\/sulindac vs CPP-1X or sulindac alone in patients with familial adenomatous polyposis: results from a double-blind, randomized Phase III trial. Paper presented at the Digestive Disease Week, San Diego, CA, 19 May 2019","DOI":"10.1016\/S0016-5085(19)36984-7"},{"issue":"9","key":"189_CR40","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/79534","volume":"6","author":"CJ Torrance","year":"2000","unstructured":"Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6(9):1024\u20131028. https:\/\/doi.org\/10.1038\/79534","journal-title":"Nat Med"},{"issue":"12","key":"189_CR41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2016.2522","volume":"315","author":"NJ Samadder","year":"2016","unstructured":"Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK (2016) Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 315(12):1266\u20131275. https:\/\/doi.org\/10.1001\/jama.2016.2522","journal-title":"JAMA"},{"issue":"5","key":"189_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/jamaoncol.2017.5431","volume":"4","author":"NJ Samadder","year":"2018","unstructured":"Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW (2018) Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial. JAMA Oncol 4(5):671\u2013677. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5431","journal-title":"JAMA Oncol"},{"issue":"7","key":"189_CR43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gut.2009.200642","volume":"59","author":"NJ West","year":"2010","unstructured":"West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59(7):918\u2013925. https:\/\/doi.org\/10.1136\/gut.2009.200642","journal-title":"Gut"},{"key":"189_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv052","author":"A Umar","year":"2015","unstructured":"Umar A, Richmond E, Kramer BS (2015) Colorectal cancer prevention and fishful thinking. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv052","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"189_CR45","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ccell.2018.07.014","volume":"34","author":"N Shenoy","year":"2018","unstructured":"Shenoy N, Creagan E, Witzig T, Levine M (2018) Ascorbic acid in cancer treatment: let the phoenix fly. Cancer Cell 34(5):700\u2013706. https:\/\/doi.org\/10.1016\/j.ccell.2018.07.014","journal-title":"Cancer Cell"},{"issue":"7","key":"189_CR46","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/1097-0142(19821001)50:7%3c1434::aid-cncr2820500733%3e3.0.co;2-f","volume":"50","author":"HJ Bussey","year":"1982","unstructured":"Bussey HJ, DeCosse JJ, Deschner EE, Eyers AA, Lesser ML, Morson BC, Ritchie SM, Thomson JP, Wadsworth J (1982) A randomized trial of ascorbic acid in polyposis coli. Cancer 50(7):1434\u20131439. https:\/\/doi.org\/10.1002\/1097-0142(19821001)50:7%3c1434:aid-cncr2820500733%3e3.0.co;2-f","journal-title":"Cancer"},{"issue":"17","key":"189_CR47","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/81.17.1290","volume":"81","author":"JJ DeCosse","year":"1989","unstructured":"DeCosse JJ, Miller HH, Lesser ML (1989) Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 81(17):1290\u20131297. https:\/\/doi.org\/10.1093\/jnci\/81.17.1290","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"189_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/cr.2016.7","volume":"26","author":"J van der Reest","year":"2016","unstructured":"van der Reest J, Gottlieb E (2016) Anti-cancer effects of vitamin C revisited. Cell Res 26(3):269\u2013270. https:\/\/doi.org\/10.1038\/cr.2016.7","journal-title":"Cell Res"},{"issue":"6266","key":"189_CR49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1126\/science.aaa5004","volume":"350","author":"J Yun","year":"2015","unstructured":"Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, Roper J, Chio II, Giannopoulou EG, Rago C, Muley A, Asara JM, Paik J, Elemento O, Chen Z, Pappin DJ, Dow LE, Papadopoulos N, Gross SS, Cantley LC (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350(6266):1391\u20131396. https:\/\/doi.org\/10.1126\/science.aaa5004","journal-title":"Science"},{"key":"189_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10010005","author":"E Rad","year":"2018","unstructured":"Rad E, Murray JT, Tee AR (2018) Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver of metabolic transformation and cancer progression. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10010005","journal-title":"Cancers (Basel)"},{"issue":"1","key":"189_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2007.05.008","journal-title":"Cancer Cell"},{"issue":"3","key":"189_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471\u2013484. https:\/\/doi.org\/10.1016\/j.cell.2006.01.016","journal-title":"Cell"},{"issue":"10","key":"189_CR53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/tri.12372","volume":"27","author":"E Cholongitas","year":"2014","unstructured":"Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P (2014) Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 27(10):1039\u20131049. https:\/\/doi.org\/10.1111\/tri.12372","journal-title":"Transpl Int"},{"issue":"4","key":"189_CR54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","volume":"18","author":"T Mathew","year":"2004","unstructured":"Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18(4):446\u2013449. https:\/\/doi.org\/10.1111\/j.1399-0012.2004.00188.x","journal-title":"Clin Transplant"},{"issue":"4 Pt 2","key":"189_CR55","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1524-4725.2004.30148.x","volume":"30","author":"S Euvrard","year":"2004","unstructured":"Euvrard S, Ulrich C, Lefrancois N (2004) Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 30(4 Pt 2):628\u2013633. https:\/\/doi.org\/10.1111\/j.1524-4725.2004.30148.x","journal-title":"Dermatol Surg"},{"issue":"6","key":"189_CR56","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"19","key":"189_CR57","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"2","key":"189_CR58","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1245\/s10434-010-1268-9","volume":"18","author":"YJ Zhang","year":"2011","unstructured":"Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, Wang BJ, Jiang FH (2011) mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol 18(2):580\u2013588. https:\/\/doi.org\/10.1245\/s10434-010-1268-9","journal-title":"Ann Surg Oncol"},{"issue":"7535","key":"189_CR59","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature13896","volume":"517","author":"WJ Faller","year":"2015","unstructured":"Faller WJ, Jackson TJ, Knight JR, Ridgway RA, Jamieson T, Karim SA, Jones C, Radulescu S, Huels DJ, Myant KB, Dudek KM, Casey HA, Scopelliti A, Cordero JB, Vidal M, Pende M, Ryazanov AG, Sonenberg N, Meyuhas O, Hall MN, Bushell M, Willis AE, Sansom OJ (2015) mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 517(7535):497\u2013500. https:\/\/doi.org\/10.1038\/nature13896","journal-title":"Nature"},{"issue":"4","key":"189_CR60","doi-asserted-by":"publisher","first-page":"e96023","DOI":"10.1371\/journal.pone.0096023","volume":"9","author":"KM Hardiman","year":"2014","unstructured":"Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER (2014) Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model. PLoS ONE 9(4):e96023. https:\/\/doi.org\/10.1371\/journal.pone.0096023","journal-title":"PLoS ONE"},{"issue":"7","key":"189_CR61","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/ajg.2016.159","volume":"111","author":"H Yuksekkaya","year":"2016","unstructured":"Yuksekkaya H, Yucel A, Gumus M, Esen H, Toy H (2016) Familial Adenomatous Polyposis; Succesful Use of Sirolimus. Am J Gastroenterol 111(7):1040\u20131041. https:\/\/doi.org\/10.1038\/ajg.2016.159","journal-title":"Am J Gastroenterol"},{"key":"189_CR62","unstructured":"Dekker E (2019) Sirolimus and familial adenomatous polyposis (FAP). 2019"},{"issue":"1","key":"189_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","volume":"31","author":"F Shihab","year":"2014","unstructured":"Shihab F, Christians U, Smith L, Wellen JR, Kaplan B (2014) Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 31(1):22\u201332. https:\/\/doi.org\/10.1016\/j.trim.2014.05.002","journal-title":"Transpl Immunol"},{"key":"189_CR64","doi-asserted-by":"publisher","first-page":"B101","DOI":"10.1016\/s0149-2918(00)89027-x","volume":"22","author":"A MacDonald","year":"2000","unstructured":"MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22:B101\u2013121. https:\/\/doi.org\/10.1016\/s0149-2918(00)89027-x","journal-title":"Clin Ther"},{"key":"189_CR65","doi-asserted-by":"crossref","unstructured":"Kemp Bohan PM, Cindass JL, Chick RC, Vreeland TJ, Hale DF, Hickerson A, Clifton GT, Peoples GE, Liss M (2020) Results of a phase Ib trial of encapsulated rapamycin in patients under active surveillance to prevent progression. Paper presented at the ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL, 6 February 2020","DOI":"10.1200\/JCO.2020.38.5_suppl.34"},{"issue":"4","key":"189_CR66","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1073\/pnas.0908682107","volume":"107","author":"KE Hung","year":"2010","unstructured":"Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U, Kucherlapati R (2010) Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 107(4):1565\u20131570. https:\/\/doi.org\/10.1073\/pnas.0908682107","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-020-00189-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-020-00189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:44:00Z","timestamp":1744177440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-020-00189-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1007\/s10689-020-00189-y","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. George E. Peoples receives consulting fees from Emtora Biosciences, the producers of eRapa. Emtora Biosciences is also the funding sponsor for a phase II study of eRapa in patients with familial adenomatous polyposis. The remaining authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript is a review article and does not involve any new data, patients, or trials that have not been previously published. No formal ethics review or approval was required to produce this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}